Adicet Bio

Adicet BioAdicet Bio
Adicet Bio

Adicet Bio

Clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

Website
DR 382014ActiveBoston, United States
Rate
Advertise here

About

Adicet Bio is a clinical-stage biotechnology company focused on discovering and developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Their proprietary platform engineers these cells with chimeric antigen receptors (CARs) to provide durable activity in patients. The company's lead product candidate, prulacabtagene leucel (prula-cel), is being developed for autoimmune indications and has received Fast Track Designation from the FDA for certain conditions.
Frequently asked

What does Adicet Bio do?

Adicet Bio is a clinical-stage biotechnology company focused on discovering and developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Their proprietary platform engineers these cells with chimeric antigen receptors (CARs) to provide durable activity in patients. The company's lead product candidate, prulacabtagene leucel (prula-cel), is being developed for autoimmune indications and has received Fast Track Designation from the FDA for certain condit…

What is Adicet Bio's revenue?

StartupHub estimates Adicet Bio's annual revenue at $28.2M (range $16.8M to $168.5M, 28% confidence), based on comparable companies in the sector.

What is Adicet Bio's valuation?

StartupHub estimates Adicet Bio's effective valuation at $1.5B (range $972.5M to $2.3B, 19% confidence), based on comparable companies in the sector.

How much funding has Adicet Bio raised?

Adicet Bio has raised a total of $389M in funding. The most recent round on record is Registered Direct Offering.

Where is Adicet Bio headquartered?

Adicet Bio is headquartered in Boston, United States.

When was Adicet Bio founded?

Adicet Bio was founded in 2014.

What industry does Adicet Bio operate in?

Adicet Bio operates in Biotech, HealthTech, Oncology, Autoimmune Diseases, Cell Therapy, Immunotherapy.

Comments

No comments yet. Be the first to share your take.